471A Stock Overview A biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
aTyr Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for aTyr Pharma Historical stock prices Current Share Price US$3.54 52 Week High US$3.84 52 Week Low US$1.27 Beta 1.1 1 Month Change 6.63% 3 Month Change 124.05% 1 Year Change 168.18% 3 Year Change -45.12% 5 Year Change -33.21% Change since IPO -90.49%
Recent News & Updates
aTyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors Dec 13
aTyr Pharma, Inc. Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis Dec 10
New minor risk - Profitability Nov 08
Independent Director recently bought €170k worth of stock Jul 25
aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Jul 22
Independent Chairman of the Board recently bought €81k worth of stock Jun 05 See more updates
aTyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors Dec 13
aTyr Pharma, Inc. Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis Dec 10
New minor risk - Profitability Nov 08
Independent Director recently bought €170k worth of stock Jul 25
aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Jul 22
Independent Chairman of the Board recently bought €81k worth of stock Jun 05
aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis May 15
aTyr Pharma, Inc., Annual General Meeting, May 22, 2024 Apr 06
New major risk - Share price stability Mar 15
New major risk - Revenue size Mar 15
Forecast to breakeven in 2026 Mar 15
aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024 Feb 29
aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis Feb 21
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild Nov 01
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes Sep 12
Independent Director recently bought €410k worth of stock May 12
Insufficient new directors Nov 16
aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest Nov 10
aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis Sep 28
aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis Aug 13
aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 05
Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod May 18
aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Insufficient new directors Apr 27
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference Apr 03
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 16
aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name Jan 14
Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020) Nov 11
aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis Sep 14
Independent Director recently bought €163k worth of stock May 22
Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019) Mar 25
aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021 Mar 17
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications Mar 16
Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor Mar 12
aTyr Pharma Announces New tRNA Synthetase Discovery Programs Feb 13
New 90-day high: €6.35 Feb 10
aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Jan 05
aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis Dec 23
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline Nov 11
aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 06
aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Oct 27
aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC Sep 18
aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020 Aug 07 Shareholder Returns 471A DE Biotechs DE Market 7D -7.8% 2.3% 0.3% 1Y 168.2% -14.0% 6.9%
See full shareholder returns
Return vs Market: 471A exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 471A's price volatile compared to industry and market? 471A volatility 471A Average Weekly Movement 17.7% Biotechs Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 471A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 471A's weekly volatility has increased from 12% to 18% over the past year.
About the Company aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
Show more aTyr Pharma, Inc. Fundamentals Summary How do aTyr Pharma's earnings and revenue compare to its market cap? 471A fundamental statistics Market cap €293.33m Earnings (TTM ) -€61.60m Revenue (TTM ) €226.85k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 471A income statement (TTM ) Revenue US$235.00k Cost of Revenue US$54.90m Gross Profit -US$54.66m Other Expenses US$9.15m Earnings -US$63.82m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.76 Gross Margin -23,261.28% Net Profit Margin -27,155.74% Debt/Equity Ratio 0%
How did 471A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/01 15:53 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources aTyr Pharma, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Birchenough BMO Capital Markets Equity Research Joseph Pantginis H.C. Wainwright & Co. Roger Song Jefferies LLC
Show 11 more analysts 
